

Publishable Summary

This deliverable is a descriptive report on amyloid PET scan quantification of all consecutive and valid participants that have been analyzed so far from the two AMYPAD trials. It includes data from 263 subjects from the Prognostic and Natural History Study (PNHS) and 585 patients from the Diagnostic and Patient Management Study (DPMS). All the analyses have been performed for the individuals whose amyloid PET imaging data passed quality control for the primary outcome variable (global cortical average normalized to the whole cerebellum). This report covers the demographic and descriptive analysis of the PNHS and DPMS data. In addition, since CSF data and RBANS scores corresponding to the PNHS subjects are available, further descriptive analysis for estimating the concordance between biomarkers, and between amyloid burden and cognition are also included in this report.

For more information: info@amypad.org

Acknowledgement: This project has received funding from the Innovative Medicines Initiative 2 Joint Undertaking under grant agreement No 115952. This Joint Undertaking receives support from the European Union's Horizon 2020 research and innovation programme and EFPIA.



innovative
medicines
initiative